A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML

Guillermo Garcia-Manero; James McCloskey; Elizabeth A. Griffiths; Karen W.L. Yee; Amer M. Zeidan; Aref Al-Kali; H. Joachim Deeg; Mitchell Sabloff; Mary Margaret Keating; Nancy Zhu; Nashat Y. Gabrail; Salman Fazal; Joseph Maly; Olatoyosi Odenike; Amy E. DeZern; Casey L. O’Connell; Gail J. Roboz; Lambert Busque; Rena Buckstein; Harshad Amin; Brian Leber; Aditi Shastri; Aram Oganesian; Harold N. Keer; Mohammad Azab; Michael R. Savona

doi:10.1080/14796694.2025.2468578

A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML

Guillermo Garcia-Manero
, James McCloskey
, Elizabeth A. Griffiths
, Karen W.L. Yee
, Amer M. Zeidan
, Aref Al-Kali
, H. Joachim Deeg
, Mitchell Sabloff
, Mary Margaret Keating
, Nancy Zhu
, Nashat Y. Gabrail
, Salman Fazal
, Joseph Maly
, Olatoyosi Odenike
, Amy E. DeZern
, Casey L. O’Connell
, Gail J. Roboz
, Lambert Busque
, Rena Buckstein
, Harshad Amin

Brian Leber, Aditi Shastri, Aram Oganesian, Harold N. Keer, Mohammad Azab, Michael R. Savona

Office of Research Compliance

University of Texas MD Anderson Cancer Center
Hackensack University Medical Center
University Health Network
Yale University
Mayo Clinic Rochester, MN
Fred Hutchinson Cancer Research Center
Pangaea Oncology, S.A.
Medica Scientia Innovation Research (MedSIR)
QEII Health Sciences Centre
University of Alberta
Gabrail Cancer Center
West Penn Allegheny Health System
Kosair Children's Hospital
The University of Chicago
Johns Hopkins University
University of Southern California
Cornell University
Hôpital Maisonneuve-Rosemont
University of Toronto
Boca Raton
Juravinski Cancer Centre
Albert Einstein College of Medicine
Inc.
Astex Pharmaceuticals
Vanderbilt University

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	929-941
Number of pages	13
Journal	Future Oncology
Volume	21
Issue number	8
DOIs	https://doi.org/10.1080/14796694.2025.2468578
State	Published - 2025

Access to Document

10.1080/14796694.2025.2468578

Cite this

Garcia-Manero, G., McCloskey, J., Griffiths, E. A., Yee, K. W. L., Zeidan, A. M., Al-Kali, A., Deeg, H. J., Sabloff, M., Keating, M. M., Zhu, N., Gabrail, N. Y., Fazal, S., Maly, J., Odenike, O., DeZern, A. E., O’Connell, C. L., Roboz, G. J., Busque, L., Buckstein, R., ... Savona, M. R. (2025). A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. Future Oncology, 21(8), 929-941. https://doi.org/10.1080/14796694.2025.2468578

@article{ac1bceee2da04706b2a7a17a68e5f27a,

title = "A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML",

author = "Guillermo Garcia-Manero and James McCloskey and Griffiths, \{Elizabeth A.\} and Yee, \{Karen W.L.\} and Zeidan, \{Amer M.\} and Aref Al-Kali and Deeg, \{H. Joachim\} and Mitchell Sabloff and Keating, \{Mary Margaret\} and Nancy Zhu and Gabrail, \{Nashat Y.\} and Salman Fazal and Joseph Maly and Olatoyosi Odenike and DeZern, \{Amy E.\} and O{\textquoteright}Connell, \{Casey L.\} and Roboz, \{Gail J.\} and Lambert Busque and Rena Buckstein and Harshad Amin and Brian Leber and Aditi Shastri and Aram Oganesian and Keer, \{Harold N.\} and Mohammad Azab and Savona, \{Michael R.\}",

year = "2025",

doi = "10.1080/14796694.2025.2468578",

language = "English",

volume = "21",

pages = "929--941",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "8",

}

Garcia-Manero, G, McCloskey, J, Griffiths, EA, Yee, KWL, Zeidan, AM, Al-Kali, A, Deeg, HJ, Sabloff, M, Keating, MM, Zhu, N, Gabrail, NY, Fazal, S, Maly, J, Odenike, O, DeZern, AE, O’Connell, CL, Roboz, GJ, Busque, L, Buckstein, R, Amin, H, Leber, B, Shastri, A, Oganesian, A, Keer, HN, Azab, M & Savona, MR 2025, 'A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML', Future Oncology, vol. 21, no. 8, pp. 929-941. https://doi.org/10.1080/14796694.2025.2468578

TY - JOUR

T1 - A plain language summary of the ASCERTAIN trial

T2 - oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML

AU - Garcia-Manero, Guillermo

AU - McCloskey, James

AU - Griffiths, Elizabeth A.

AU - Yee, Karen W.L.

AU - Zeidan, Amer M.

AU - Al-Kali, Aref

AU - Deeg, H. Joachim

AU - Sabloff, Mitchell

AU - Keating, Mary Margaret

AU - Zhu, Nancy

AU - Gabrail, Nashat Y.

AU - Fazal, Salman

AU - Maly, Joseph

AU - Odenike, Olatoyosi

AU - DeZern, Amy E.

AU - O’Connell, Casey L.

AU - Roboz, Gail J.

AU - Busque, Lambert

AU - Buckstein, Rena

AU - Amin, Harshad

AU - Leber, Brian

AU - Shastri, Aditi

AU - Oganesian, Aram

AU - Keer, Harold N.

AU - Azab, Mohammad

AU - Savona, Michael R.

PY - 2025

Y1 - 2025

UR - https://www.scopus.com/pages/publications/105000429821

U2 - 10.1080/14796694.2025.2468578

DO - 10.1080/14796694.2025.2468578

M3 - Article

C2 - 40051275

AN - SCOPUS:105000429821

SN - 1479-6694

VL - 21

SP - 929

EP - 941

JO - Future Oncology

JF - Future Oncology

IS - 8

ER -

A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML

Access to Document

Other files and links

Fingerprint

Cite this